Manifest Peptides

Manifest Peptides is a U.S.-based research compound supplier focused exclusively on the GLP receptor agonist segment, with 3 active listings on Peptides.SO covering the three most prominent research compounds in contemporary metabolic peptide science: Semaglutide, Tirzepatide, and Retatrutide. The company's singular catalog focus makes it one of the more specialized GLP-1 research suppliers in the market, offering researchers clean access to the full GLP receptor pharmacology progression without catalog noise across unrelated compound categories.

The core of Manifest Peptides' catalog centers on GLP-1 receptor agonism and its mechanistic extensions. Semaglutide, a GLP-1 receptor agonist structurally derived from human GLP-1 with a C-18 fatty acid side chain enabling half-life extension, is the foundational compound in the catalog. In vitro and animal model research has characterized Semaglutide's effects on glucose-stimulated insulin secretion from pancreatic beta cells, GLP-1 receptor-mediated suppression of glucagon release from alpha cells, slowing of gastric emptying via vagal nerve signaling, and dose-dependent reduction in food intake via hypothalamic satiety circuits. The receptor binding affinity of Semaglutide at the GLP-1R has been studied extensively relative to native GLP-1 and earlier-generation analogs such as Liraglutide, with Semaglutide's albumin-binding fatty acid chain conferring greater plasma half-life and sustained receptor occupancy in preclinical models.

Tirzepatide, the second compound in the Manifest Peptides catalog, represents the dual-agonism extension of GLP-1 receptor research by simultaneously targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) alongside GLP-1R. The addition of GIP receptor activity introduces mechanistically distinct effects studied in preclinical contexts: GIPR activation has been associated with differential adipokine secretion profiles, augmented brown adipose tissue thermogenesis through sympathetic nervous system potentiation, and modulation of bone mineral density via GIPR expression in osteoblasts. Comparative studies in rodent models have characterized how dual GIP/GLP-1 receptor agonism produces metabolic outcomes that differ quantitatively and qualitatively from GLP-1 monotherapy, particularly in the magnitude of fat mass reduction and the relative contributions of energy expenditure versus caloric restriction. For researchers studying the GIP receptor pathway's contribution to metabolic biology, Tirzepatide offers a validated dual-agonist scaffold with extensive published preclinical literature.

Manifest Peptides' three-listing catalog (Semaglutide, Tirzepatide, Retatrutide) is priced at $79.99–$129.99 per listing. The affiliate URLs in the current data file reference unrelated product pages (shampoo, bath oil), suggesting that the link data may be stale and the actual product URLs differ. Researchers should verify current pricing and product availability directly on the supplier's website.

Retatrutide, the third and most pharmacologically complex compound in the Manifest Peptides catalog, adds glucagon receptor (GCGR) agonism to the dual GLP-1R/GIPR profile, creating a triple receptor agonist for researchers studying the combined effects of all three incretin-related receptor pathways. Glucagon receptor activation independently drives hepatic glucose production, lipid mobilization from adipose tissue, and enhanced fat oxidation — effects that are modulated by simultaneous GLP-1R and GIPR activity in the Retatrutide molecule. Animal model research studying triple agonism has documented augmented effects on hepatic lipid clearance and whole-body energy expenditure compared to dual agonism, with mechanistic interest centering on how GCGR-driven fat oxidation synergizes with GLP-1R-mediated caloric restriction and GIPR-mediated thermogenesis. Retatrutide represents a leading edge compound for researchers seeking to understand the ceiling of GLP receptor pharmacology in preclinical metabolic models.

Manifest Peptides operates with a research-first positioning for the GLP-1 agonist catalog, making the company appropriate for academic and institutional laboratories studying incretin biology, adipose tissue physiology, pancreatic beta cell function, and central nervous system regulation of energy homeostasis. All Manifest Peptides products are supplied exclusively for in-vitro laboratory research and are not intended for human consumption, clinical use, or veterinary application.